Immunic (IMUX) Insider Tamar Howson Buys 25,370 Shares

On June 29, 2026, Tamar Howson purchased 25,370 shares of IMUX. This transaction was not made under a prearranged 10b5-1 trading plan.

Insider Buying and Selling at Immunic, Inc.

Tamar Howson wasn't the only insider buying shares of IMUX on June 29, 2026. Jon Congleton acquired 50,740 shares, while Jason Tardio, the President and COO, added 253,000 shares to his holdings. Glenn Whaley, the Chief Financial Officer, bought 120,000 shares. Joerg Neermann and Daniel Vitt also participated, purchasing 25,370 and 445,000 shares, respectively. None of these transactions were part of planned trading arrangements.

Other Institutional Activity in IMUX

Several institutional investors have also been active in IMUX. Aberdeen Group PLC reduced its holdings by 7,419,547 shares, leaving it with 824,394 shares valued at about $9.15 million, a 90% decrease. Similarly, BVF Inc/IL cut its position by 6,887,675 shares, now holding 765,297 shares worth approximately $8.49 million, also a 90% reduction. Avidity Partners Management LP decreased its stake by 4,029,470 shares, ending with 669,941 shares valued at $7.44 million, an 85.7% drop. Meanwhile, Vanguard Capital Management LLC and Soleus Capital Management, L.P. both opened new positions with 513,832 and 450,000 shares, respectively, valued at $5.70 million and $4.99 million.

Immunic, Inc. Stock Up 45.1%

Shares of IMUX traded near $15.30 on Tuesday. Institutional investors have been adjusting their positions in the company, which may impact its stock performance. The recent insider buying activity suggests confidence from within the company.

Analysts Set New Price Targets

On May 22, 2026, B. Riley Securities maintained its buy rating for IMUX with a price target of $27. Earlier, on April 30, 2026, HC Wainwright & Co. also maintained a buy rating, setting a target of $22. Stifel initiated coverage on April 17, 2026, with a buy rating and a $2.5 price target. The consensus among analysts remains positive, with a general buy recommendation and targets ranging up to $27.

Bottom Line

Tamar Howson's recent purchase of IMUX shares on June 29, 2026, is part of a broader trend of insider buying, which can be a sign of confidence in the company's future. Institutional investors have made significant adjustments to their positions, with some reducing their stakes while others have entered new positions. Analysts continue to rate IMUX as a buy, with optimistic price targets reflecting positive sentiment about the company's potential.